Treatment Guideline Chart
Cardiovascular disease (CVD) development is closely related to lifestyle characteristics and associated risk factors.
There is overwhelming scientific evidence that lifestyle modifications and reduction of risk factors can slow the development of CVD both before and after the occurrence of a CV event.
Primary CVD prevention is aimed at the healthy population and population at risk (with ≥1 CV risk factors) that has not had a CV event while secondary CVD prevention is instituted for those who have confirmed CVD or had a first index event.

Cardiovascular%20disease%20prevention Management

Management of Other Risk Factors

Blood Pressure (BP) Control

  • Goal1: BP <140/90 mmHg in all patients, though BP targets should be individualized
    • Target SBP range to <130-139 mmHg in individuals ≥65 years old 
    • DBP <80 mmHg is recommended in all treated patients
  • BP should be recorded at each visit
  • Start lifestyle modification in all patients: Weight reduction, eating fruits, vegetables and low-fat dairy products, reducing salt intake, supplementing with dietary potassium (3.5-5 g/day), limiting alcohol intake, and increasing physical activity
  • If BP goals are not achieved with lifestyle modifications, start drug therapy individualized for each patient, considering age, race or need for drugs with specific benefits, CVD risk, or presence of hypertension-mediated organ damage
  • ACE inhibitors and ARBs as well as calcium channel blockers, thiazide or thiazide-like diuretics and, for certain indications, beta-blockers are commonly used in the treatment of CV disorders, eg hypertension, coronary artery disease (CAD) and congestive heart failure 
    • Risk of COVID-19 infection or risk of developing severe COVID-19 complications is not increased with prior or current treatment with ACE inhibitors or ARBs thus treatment should be continued as prescribed
  • Please see Hypertension disease management chart for further information

1Recommendations for BP treatment goals may vary between countries. Please refer to available guidelines from local health authorities. 

Lipid Management

  • Reduction of plasma TC by 10% decreased the incidence of CAD by 25% after 5 years, and a reduction of LDL-C by 40 mg/dL (1 mmol/L) was accompanied by 20% reduction in CHD events
  • Goal for LDL-C based on risk groups:
    • Low risk <116 mg/dL (<3 mmol/L)
    • Moderate risk <100 mg/dL (<2.6 mmol/L) 
    • High risk <70 mg/dL (<1.8 mmol/L)
    • Very high risk <55 mg/dL (<1.4 mmol/L)
    • If LDL-C goals based on risk groups cannot be achieved, aim to decrease LDL-C by ≥50% from baseline and reduce other risk factors
  • General goal:
    • TC <200 mg/dL (<5.18 mmol/L)
    • HDL-C as high as possible but at least >40 mg/dL in men (>1.0 mmol/L) and >45 mg/dL (>1.2 mmol/L) in women
    • TG <150 mg/dL (<1.69 mmol/L)
      • If TG is ≥200 mg/dL (≥2.26 mmol/L), non-HDL-C should be <130 mg/dL (<3.37 mmol/L) or <100 mg/dL (<2.59 mmol/L) for very high-risk individuals
    • Apolipoprotein B <90 mg/dL in high-risk patients, <80 mg/dL in very high-risk patients with established ASCVD or DM with ≥1 additional risk factor, and <70 mg/dL in extreme-risk patients
  • Therapeutic lifestyle changes should be advised to all patients above the goal range
  • Stress the importance of smoking cessation, weight reduction and physical activity
  • Lipid-lowering therapy may be initiated
    • Secondary causes of dyslipidemia (such as hypothyroidism, alcohol abuse, Cushing’s syndrome, diseases of liver and kidneys) should be ruled out before initiating therapy
    • Statins are usually used in both primary and secondary CVD events in high-risk patients
      • First drugs of choice in high-risk patients with hypertriglyceridemia for decreasing CVD risk  
      • Initiation of statin therapy is recommended for patients 40-75 years with LDL-C of 70-189 mg/dL without clinical ASCVD or DM, patients ≥21 years of age with primary LDL-C ≥190 mg/dL, and patients 40-75 years with DM
      • May be considered for primary prevention in patients ≥70 years old if at high risk or above
      • First-line therapy in patients ≥75 years old with clinical ASCVD unless contraindicated
    • Fibrates have not been found to reduce CV events but may be used in the treatment of severe hypertriglyceridemia
    • Individuals with TG >500 mg/dL should be started with fibrate in addition to statin to prevent acute pancreatitis
  • Current evidence shows that lipid-lowering therapy is safe in patients with COVID-19 infection 
    • Lipid-lowering therapy should be continued in patients with confirmed COVID-19 diagnosis and abnormal liver function tests (LFTs) unless alanine transaminase (ALT) or aspartate transaminase (AST) progressively increases, a significant drug-drug interaction between the lipid-lowering agents and COVID-19 drugs has been identified, or patient is critically ill and/or cannot take oral medications   
    • Bile acid sequestrants and Niacin may be temporarily discontinued in patients with COVID-19 infection due to the lack of evidence of CV outcome data 
  • Please see Dyslipidemia disease management chart for further information

Diabetes Management

  • Diabetic patients (type 1 or type 2) are at increased risk for CVD and have worse outcomes after surviving a cardiovascular disease event
  • Good glycemic control substantially reduces the risk of cardiovascular events and microvascular diseases
  • Treatment of DM is always recommended regardless of the overall risk of vascular disease
  • Start appropriate therapy to achieve near-normal fasting plasma glucose (<7 mmol/L) or as indicated by near-normal HbA1c, starting with a healthy diet and exercise
  • The goal, in general, is HbA1c <7% (<53 mmol/mol) for both type 1 and 2 DM, but since HbA1c may vary with patients’ ethnicity/race, values must be individualized
    • A HbA1c goal of ≤6.5% (≤48 mmol/mol) should be considered in type 2 DM patients with good health status and without ASCVD
    • To reduce the risk of hypoglycemia, individualize glycemic goals based on patient’s profile
  • Lifestyle modification with BP and lipid management are recommended in all diabetic patients
    • If lifestyle modification fails, oral antidiabetic medications, preferably Metformin followed by consideration of a sodium-glucose linked transporter/co-transporter 2 (SGLT2) inhibitor or a glucagon-like peptide-1 (GLP-1) receptor agonist, or Insulin should be added to the treatment regimen
  • Lipid-lowering drugs are recommended for all type 2 DM patients and for type 1 DM patients >40 years old
    • May be considered in patients <40 years at high risk, with multiple risk factors and microvascular complications
  • Patients with diabetes require strict blood glucose monitoring and prevention of diabetes complications during the COVID-19 pandemic in order to keep their susceptibility low and to prevent severe COVID-19 disease courses 
    • According to the 2023 American Diabetes Association guidelines, there is no clear indication to modify prescribing of antidiabetic medications in patients with diabetes and COVID-19 disease   
  • Please see Diabetes Mellitus disease management chart for further information

Obesity/Overweight Management

  • Weight loss is indicated for patients with WHO BMI of >30 kg/m2 or 25-29.9 kg/m2 with risk factors (eg DM, prediabetes, hypertension, dyslipidemia, waistline >88 cm for women/>102 cm in men) or obesity-associated comorbidities
  • Goal is 5-10% weight loss in 6 months and weight maintained within 2 years  
  • Lifestyle modifications (diet modification, increased physical activity, weight management) are recommended in all obese/overweight patients
    • Comprehensive lifestyle intervention is recommended if no weight loss is seen with lifestyle modifications
  • Preventive measures including lifestyle modifications decrease the risk of cardiometabolic diseases which in turn reduce the risk of severe COVID-19 infection 
  • Addition of pharmacological therapy is recommended if patient continues to gain weight or is unable to lose weight even with comprehensive lifestyle interventions
  • May refer patients for bariatric surgery if all interventions fail and patient has a BMI ≥40 kg/m2 or BMI ≥35 kg/mwith comorbidities
  • Please see Obesity disease management chart for further information

Cardiac Rehabilitation

  • Comprehensive outpatient CV rehabilitation program is recommended in patients with acute coronary syndrome, chronic angina, post coronary artery bypass surgery (CABG) or post percutaneous coronary intervention
    • It is recommended for patients after ASCVD events and/or revascularization and those with heart failure (particularly heart failure with reduced ejection fraction) to have an exercise-based cardiac rehabilitation and prevention program to improve patient outcomes 

Depression Management

  • Screening for depression is advisable in patients with recent CABG or MI 
  • Management of depression has not been shown to improve cardiovascular disease prognosis but may be advisable for its other clinical effects



  • Patients with CVD or other atherosclerotic vascular disease (such as PAD, CAD) should have an annual influenza vaccination
  • Some studies support the association of pneumococcal pneumonia and the development of concurrent acute cardiac events (eg MI, arrhythmia, new or worsening of congestive heart failure [CHF]), hence they recommend pneumococcal vaccination in high-risk populations
  • Influenza and pneumococcal vaccinations are important in decreasing the risk of respiratory infection and subsequent complications in patients with CVD during the COVID-19 pandemic
  • All CVD patients are encouraged to receive COVID-19 vaccination as the risk of severe COVID-19 infection is high
Editor's Recommendations
Special Reports